B.C. HIV/AIDS Drug Treatment Programcfenet.ubc.ca/sites/default/files/uploads/publications/...2....

B.C. HIV/AIDSDrug Treatment Program

Monthly ReportJuly 2017

BC Centre for Excellence in HIV/AIDSDrug Treatment Program

St. Paul’s Hospital608 - 1081 Burrard StreetVancouver, BCV6Z 1Y6

Tel: 604.806.8202Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677St. Paul’s Hospital Pharmacy Hotline: 1.888.511.6222Website: www.cfenet.ubc.caEmail: [email protected]

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)

© 2017 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE’s Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report’s date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS’ (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE’s commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE’s treatment guidelines.

TABLE OF CONTENTS

1. List of Figures

1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants1.5 BC-CfE Enrolment: New Antiretroviral Participants1.6 Percent Distribution of Active Participants by CD4 Count1.7 Percent Distribution of Inactive Participants by CD4 Count1.8 Active and Inactive Participants1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient1.12 Distribution of Participants on Protease Inhibitor by Ingredient1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient1.14 Distribution of Participants on Non-Nucleosides by Ingredient1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient1.18 Baseline CD4 for Antiretroviral First Starts1.19 DTP Participants with PVL Measurement within previous five years, and never on ART1.20 Cumulative Resistance Testing Results by Resistance Category1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program2.4 BC-CfE Enrolment2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient2.7 Number of Participants on Protease Inhibitor by Ingredient2.8 Number of Participants on Non-Nucleosides by Ingredient2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class2.11 Baseline CD4 for Antiretroviral First Starts2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

Table of Contents, cont’d...

3. Health Authority Maps

3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants3.2 Interior Health Authority & Kelowna3.3 Fraser Health Authority & Surrey3.4 Vancouver Coastal Health Authority & Vancouver3.5 Vancouver Island Health Authority & Victoria3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH4.1 Distribution of Participants in BC-CfE Registries by Age and Gender4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH4.4 Distribution of Participants in BC-CfE Registries by Age and Gender4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL4.7 Distribution of Participants in BC-CfE Registries by Age and Gender4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND4.10 Distribution of Participants in BC-CfE Registries by Age and Gender4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH4.13 Distribution of Participants in BC-CfE Registries by Age and Gender4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

5.1 Drug Names and Definitions

1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

N = 7236July 2017

FRASERINTERIORNORTHERNVANCOUVER COASTALVANCOUVER ISLAND

Health Authority

1777474206

3864880

4009978

451163

1377375128

3413717

Definitions:On antiretroviral therapy defined as being on treatment in the current monthUnknown/not stated defined as being on treatment in the current month, and city of residence unknown

Male Female All

0

1 - 99

100 - 499

500 - 999

1000+

Northern

Interior

Fraser

VancouverCoastal

VancouverCoastalVancouver

Island

Unknown/not stated: 35

Total: 7236

6010 1191 7201

1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

Num

ber

of P

artic

ipan

ts

(July 2012 - July 2017)

2012 2013 2014 2015 2016 2017

Date

0

500

1,000

1,500

2,000

2,500

3,000

MDRT

Other

Boosted PI+ 2 NRTIs

Un-boosted PI+ 2 NRTIs

Integrase+ 2 NRTIs

NNRTI+ 2 NRTIs

1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

% o

f Par

ticip

ants

(July 2012 - July 2017)

2012 2013 2014 2015 2016 2017

Date

0

20

40

60

80

100 Boosted PI+ 2 NRTIs

Un-boostedPI + 2 NRTIs

Integrase+ 2 NRTIs

NNRTI+ 2 NRTIs

MDRT

Other

1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants

Num

ber

of P

artic

ipan

ts

(July 2012 - July 2017)

2012 2013 2014 2015 2016 2017

Date

-50

-25

0

25

50

75

100

125

150

175

200

225

250Starts

New Inactive

Net Change

1.5 BC-CfE Enrollment: New Antiretroviral Participants

Num

ber

of P

artic

ipan

ts

(July 2012 - July 2017)

2012 2013 2014 2015 2016 2017

Date

0

25

50

75

100

125

150

175

200First Starts

ExperiencedStarts

1.6 Percent Distribution of Active Participants by CD4 Count

% o

f Par

ticip

ants

(July 2012 - July 2017)

2012 2013 2014 2015 2016 2017

Date

0

20

40

60

80

100CD4: > 500

CD4: 100-199

CD4:200-349

CD4: 350-500

CD4: < 100

1.7 Percent Distribution of Inactive Participants by CD4 Count

% o

f Par

ticip

ants

(July 2012 - July 2017)

2012 2013 2014 2015 2016 2017

Date

0

20

40

60

80

100CD4: > 500

CD4: 100-199

CD4:200-349

CD4: 350-500

CD4: < 100

1.8 Active and Inactive Participants

Num

ber

of P

artic

ipan

ts

(July 2012 - July 2017)

2012 2013 2014 2015 2016 2017

Date

0

500

1,000

1,500

2,000

2,500

3,000

3,500

4,000

4,500

5,000

5,500

6,000

6,500

7,000

7,500

8,000Active

Inactive

1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs

% o

f Par

ticip

ants

(July 2012 - July 2017)

2012 2013 2014 2015 2016 2017

Date

0

20

40

60

80

100

3 drugs

4 drugs

5 or moredrugs

Less than3 drugs

1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

Num

ber

of P

artic

ipan

ts

(July 2012 - July 2017)

2012 2013 2014 2015 2016 2017

Date

0

500

1,000

1,500

2,000

2,500

3,000

3,500

4,000

4,500

5,000Lamivudine

Didanosine

Abacavir

Emtricitabine

Stavudine

Zidovudine

Tenofovir<TDF>

Tenofovir<TAF>

1.11 Distribution of Participants on Nucleoside/Nucleotide Analoguesat the time of first start of ARV Therapy by INGREDIENT

Num

ber

of P

artic

ipan

ts

(July 2012 - July 2017)

2012 2013 2014 2015 2016 2017

Date

0

10

20

30

40

50

60Lamivudine

Didanosine

Abacavir

Emtricitabine

Stavudine

Zidovudine

Tenofovir(TDF>

Tenofovir<TAF>

1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT

Num

ber

of P

artic

ipan

ts

(July 2012 - July 2017)

2012 2013 2014 2015 2016 2017

Date

0

500

1,000

1,500

2,000

2,500Atazanavir

Indinavir

Darunavir

Saquinavir

Lopinavir

Nelfinavir

Tipranavir

Ritonavir

(fos)amprenavir

1.13 Distribution of Participants on Protease Inhibitorat the time of first start of ARV Therapy by INGREDIENT

Num

ber

of P

artic

ipan

ts

(July 2012 - July 2017)

2012 2013 2014 2015 2016 2017

Date

0

10

20

30

40

50Atazanavir

Indinavir

Darunavir

Saquinavir

Lopinavir

Nelfinavir

Tipranavir

Ritonavir

(fos)amprenavir

1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT

Num

ber

of P

artic

ipan

ts

(July 2012 - July 2017)

2012 2013 2014 2015 2016 2017

Date

0

100

200

300

400

500

600

700

800

900

1,000

1,100

1,200

1,300

1,400

1,500

1,600Etravirine

Nevirapine

Efavirenz

Rilpivirine

Delavirdine

1.15 Distribution of Participants on Non-Nucleosidesat the time of first start of ARV Therapy by INGREDIENT

Num

ber

of P

artic

ipan

ts

(July 2012 - July 2017)

2012 2013 2014 2015 2016 2017

Date

0

5

10

15

20Etravirine

Nevirapine

Efavirenz

Rilpivirine

Delavirdine

1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT

Num

ber

of P

artic

ipan

ts

(July 2012 - July 2017)

2012 2013 2014 2015 2016 2017

Date

0

100

200

300

400

500

600

700

800

900

1,000

1,100

1,200

1,300

1,400

1,500

1,600

1,700

1,800

1,900

2,000Elvitegravir

Maraviroc

Raltegravir

Enfuvirtide

Dolutegravir

1.17 Distribution of Participants on Entry/Integrase Inhibitorsat the time of first start of ARV Therapy by INGREDIENT

Num

ber

of P

artic

ipan

ts

(July 2012 - July 2017)

2012 2013 2014 2015 2016 2017

Date

0

2

4

6

8

10

12

14

16

18

20Elvitegravir

Maraviroc

Raltegravir

Enfuvirtide

Dolutegravir

1.18 Baseline CD4 for Antiretroviral First Starts

% o

f Par

ticip

ants

(July 2012 - July 2017)

2012 2013 2014 2015 2016 2017

Date

0

20

40

60

80

100CD4: > 500

CD4: 100-199

CD4:200-349

CD4: 350-500

CD4: < 100

1.19 DTP Participants with PVL Measurement within previous five years, and never on ART

Num

ber

of P

artic

ipan

ts

(July 2012 - July 2017)

2012 2013 2014 2015 2016 2017

Date

0

1,000

2,000

3,000

4,000

5,000

6,000

7,000

8,000

9,000

10,000

11,000

12,000with PVL

with PVL, no ART

1.20 Cumulative Resistance Testing Results by Resistance Category

Num

ber

of P

artic

ipan

ts

(July 2012 - July 2017)

2012 2013 2014 2015 2016 2017

Date

0

500

1,000

1,500

2,000

2,500

3,000

3,500

4,000

4,500

5,000

5,500

6,000

6,500

7,000

7,500

8,000

8,500

9,000

9,500

10,000

NNRTIresistant

PIresistant

Ever tested

Non-LamivudineNRTI resistant

Lamivudineresistant

Entry/Integraseresistant

1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

% o

f Par

ticip

ants

(July 2012 - July 2017)

2012 2013 2014 2015 2016 2017

Date

0

10

20

30

40

50

60

70

80

90

100

NNRTIresistant

PIresistant

Ever tested

Non-LamivudineNRTI resistant

Lamivudineresistant

Entry/Integraseresistant

2.1 Duration of ARV treatment in the Province of BC, 1987-2017 (for HIV+ persons currently on treatment)

1987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017

Start Year

57

57623774

155106137405314235201166153158185196229230293353392353400339337347356375197

57

57613869

14292

121361290210171138128137166172194203270306338298350293282308318320179

3333333333333333333333333333333

<40<40<40<40<40<40<40<40<40<40<40<40<40<40<40<40<40<40<40<40<40<40<40<40<40<40<40<40<40<40<40

630590530530555560510520570580620550555565580560580590590560600620630620670660630690660593534

Duration (years)Median

2525242323232220211817161616161514131211109876543210

57

51563261

14293

121363294214186154136142165176206208266318348317363308293302317342194

MaleCurrent PVL(n) Median

Current CD4(n) MedianFemale All

002137

16152462384342373328304147455269777573636957557022

57

59624176

158107145423328253213175161165196213241248322375415373423356351365373390201

Current ARVMedian

Definitions:On treatment defined as being on ARV therapy in the specified month and not reported deceasedDuration defined as cumulative years on ARV therapy, excluding periods of treatment interruptionCurrent CD4 and PVL tests defined as tests done in the last 6 months (most recent)Current ARV defined as number of ARV drugs in the current regimen

6024 1196 7220Total:

2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

JAN-2016FEB-2016MAR-2016APR-2016MAY-2016JUN-2016JUL-2016AUG-2016SEP-2016OCT-2016NOV-2016DEC-2016JAN-2017FEB-2017MAR-2017APR-2017MAY-2017JUN-2017JUL-2017

MON-YYYY

737735737734747739749750752747742752749755746748749753760

6970698969957014704370627052706971087138716971927182713471867180722872497236

Median # of therapy days

Definitions:Active patient defined as being on ARV treatment in the specified monthTherapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)PVL and CD4 tests defined as tests done in the specified month

# of patients # of patientswith PVL test Median PVL

# of patientswith CD4 test Median CD4

<40<40<40<40<40<40<40<40<40<40<40<40<40<40<40<40<40<40<40

2262206421552053207121791949206822142153211018722324191422011965228021191964

2023186519581864188519911760187719991935190217062066173219961744199918711667

590590590580590610600590600600580620590590600590590600590

2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program


MON-YYYY

2278231522962286237423582309222322762449249025112499225924482408254326492561

1512150415111515149915101534155815451519151615171533158915441562153215231543

Median # days of off therapy

Definitions:Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)Days off therapy defined as number of days elapsed since last ARV treatmentPVL and CD4 tests defined as tests done in the specified month

# of patients # of patientswith PVL test Median PVL

# of patientswith CD4 test Median CD4

<40353130<50<40

76<50158240<40

1007122140

1387635517148153288

11683878779728194967473528879

10195827770

104748374695675788070584478678985686756

465380440360350505460360360415380480417400360420420490495

2.4 BC-CfE Enrollment

Definitions:Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BCCurrently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the pastDeceased defined as deceased in the specified month, and being on ARV treatment in the previous monthFirst Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVsNew Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous monthNet Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)

MON-YYYYCurrently onARV Therapy

Currently offARV Therapy Deceased First Starts

NewInactive

ExperiencedStarts

NetChange

CumulativePatients


6940696069686987701870327015703170737101712771497144710471527146720572287220

16182420233425402722272522241920222412

152178170166159163136165179161181154140136187144173149135

168163173157142167157172151138160142144185139155127136151

1512150415111515149915101534155815451519151615171533158915441562153215231543

-1220

8193114

-171642282622-5

-4048-65923-8

95967

121110

511201121101712

794

12409124371247112505125361257912611126711271412745127911283112863128971292312955129891301913037

2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs


MON-YYYY

6405643664426464649564996496650965466578660366356615657966296633666866956679

3 Drugs

6970698969957014704370627052706971087138716971927182713471867180722872497236

All ARV

0.83% 0.84% 0.77% 0.77% 0.81% 0.85% 0.81% 0.81% 0.82% 0.81% 0.85% 0.86% 0.85% 0.84% 0.83% 0.82% 0.86% 0.79% 0.86%

Less than3 Drugs%

91.89% 92.09% 92.09% 92.16% 92.22% 92.03% 92.12% 92.08% 92.09% 92.15% 92.10% 92.26% 92.11% 92.22% 92.25% 92.38% 92.25% 92.36% 92.30%

3 Drugs%

100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%

Total%Less than

3 Drugs

58595454576057575858616261606059625762

446435438439437447442447447445446437443440438429439439434

4 Drugs

6.40% 6.22% 6.26% 6.26% 6.20% 6.33% 6.27% 6.32% 6.29% 6.23% 6.22% 6.08% 6.17% 6.17% 6.10% 5.97% 6.07% 6.06% 6.00%

4 Drugs%

61596157545657565757595863555959595861

5 or moreDrugs

0.88% 0.84% 0.87% 0.81% 0.77% 0.79% 0.81% 0.79% 0.80% 0.80% 0.82% 0.81% 0.88% 0.77% 0.82% 0.82% 0.82% 0.80% 0.84%

5 or moreDrugs%

Definitions:Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

Definitions:Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASSAll is defined as number of patients on ARV treatment which contains INGREDIENT;% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

JAN-2016

FEB-2016

MAR-2016

APR-2016

MAY-2016

JUN-2016

JUL-2016

AUG-2016

SEP-2016

OCT-2016

NOV-2016

DEC-2016

JAN-2017

FEB-2017

MAR-2017

APR-2017

MAY-2017

JUN-2017

JUL-2017

lamivudine abacavir zidovudine stavudine didanosine

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

4 4 0 0 0

10 9 1 0 0

9 7 1 0 0

12 9 3 0 0

8 8 0 0 0

11 11 0 0 0

9 9 0 0 0

11 11 0 0 0

14 12 0 0 0

11 11 0 0 0

17 17 0 0 0

7 7 0 0 0

13 13 0 0 0

12 10 1 0 0

7 7 0 0 0

13 12 1 0 0

9 9 0 0 0

6 6 0 0 0

8 8 0 0 0

Initial All Initial All Initial All Initial All Initial All2818 2485 93 11 8

2851 2519 94 11 8

2877 2542 94 11 8

2893 2567 93 11 8

2894 2578 92 11 7

2924 2602 91 12 7

2903 2583 90 12 7

2936 2626 80 11 7

2969 2659 81 8 6

2997 2689 82 9 7

3023 2722 78 7 6

3058 2753 77 6 6

3068 2772 75 5 6

3074 2783 71 5 6

3105 2824 69 6 5

3115 2835 68 6 6

3158 2880 73 6 5

3169 2902 71 6 5

3197 2927 72 6 5

42% 37% 1% 0% 0%

42% 37% 1% 0% 0%

43% 38% 1% 0% 0%

43% 38% 1% 0% 0%

43% 38% 1% 0% 0%

43% 38% 1% 0% 0%

43% 38% 1% 0% 0%

43% 38% 1% 0% 0%

43% 39% 1% 0% 0%

43% 39% 1% 0% 0%

44% 39% 1% 0% 0%

44% 40% 1% 0% 0%

44% 40% 1% 0% 0%

44% 40% 1% 0% 0%

45% 41% 1% 0% 0%

45% 41% 1% 0% 0%

45% 41% 1% 0% 0%

45% 41% 1% 0% 0%

46% 42% 1% 0% 0%

19% 19% 0% 0% 0%

36% 32% 4% 0% 0%

26% 21% 3% 0% 0%

35% 26% 9% 0% 0%

26% 26% 0% 0% 0%

26% 26% 0% 0% 0%

28% 28% 0% 0% 0%

19% 19% 0% 0% 0%

33% 28% 0% 0% 0%

35% 35% 0% 0% 0%

37% 37% 0% 0% 0%

18% 18% 0% 0% 0%

41% 41% 0% 0% 0%

35% 29% 3% 0% 0%

27% 27% 0% 0% 0%

41% 38% 3% 0% 0%

26% 26% 0% 0% 0%

20% 20% 0% 0% 0%

44% 44% 0% 0% 0%

tenofovir <TAF>

0 0% 0 0%

0 0% 0 0%

0 0% 0 0%

0

0

1

0

6

3

0

0

0

0

0

0

0

1

2

0

Initial All

5

6

9

9

22

25

26

35

35

46

50

78

96

120

144

161

0%

0%

0%

0%

0%

0%

0%

1%

1%

1%

1%

1%

1%

2%

2%

2%

0%

0%

2%

0%

10%

7%

0%

0%

0%

0%

0%

0%

0%

3%

7%

0%

tenofovir <TDF>

17

18

26

22

23

31

23

42

27

20

29

33

19

22

19

19

24

22

10

Initial All4165

4135

4112

4103

4120

4117

4113

4097

4102

4098

4088

4077

4051

3982

4000

3963

3935

3900

3855

62%

61%

61%

60%

61%

60%

60%

60%

60%

59%

59%

59%

58%

58%

57%

57%

56%

55%

55%

81%

64%

76%

65%

74%

72%

72%

71%

63%

65%

63%

83%

59%

65%

73%

59%

71%

73%

56%

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)


JAN-2016

FEB-2016

MAR-2016

APR-2016

MAY-2016

JUN-2016

JUL-2016

AUG-2016

SEP-2016

OCT-2016

NOV-2016

DEC-2016

JAN-2017

FEB-2017

MAR-2017

APR-2017

MAY-2017

JUN-2017

JUL-2017

0 0% 0 0%

0 0% 0 0%

0 0% 0 0%

0 0% 0 0%

0 0% 0 0%

0 0% 0 0%

0 0% 0 0%

0 0% 0 0%

0 0% 0 0%

0 0% 0 0%

0 0% 0 0%

0 0% 0 0%

0 0% 0 0%

0 0% 0 0%

0 0% 0 0%

0 0% 0 0%

0 0% 0 0%

0 0% 0 0%

0 0% 0 0%

emtricitabine

17

18

25

22

23

32

23

48

29

20

29

33

19

22

19

19

25

24

10

Initial All3848

3828

3809

3812

3834

3829

3830

3831

3847

3848

3852

3843

3828

3771

3803

3792

3800

3800

3764

57%

57%

56%

56%

56%

56%

56%

56%

56%

56%

56%

55%

55%

55%

55%

55%

54%

54%

54%

81%

64%

74%

65%

74%

74%

72%

81%

67%

65%

63%

83%

59%

65%

73%

59%

74%

80%

56%

2.7 Number of Participants on Protease Inhibitor by INGREDIENT

Definitions:Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASSAll is defined as number of patients on ARV treatment which contains INGREDIENT;% is calculated as ratio of "All" and number of patients whose treatment is of given CLASSRitonavir - greater than 400 mg total daily dose

JAN-2016

FEB-2016

MAR-2016

APR-2016

MAY-2016

JUN-2016

JUL-2016

AUG-2016

SEP-2016

OCT-2016

NOV-2016

DEC-2016

JAN-2017

FEB-2017

MAR-2017

APR-2017

MAY-2017

JUN-2017

JUL-2017

(fos)amprenavir atazanavir darunavir lopinavir nelfinavir ritonavir saquinavir

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 5 5 1 0 0 0

0 6 6 1 0 0 0

0 4 11 1 0 0 0

0 1 13 0 0 0 0

0 2 10 0 0 0 0

0 3 12 0 0 0 0

0 3 11 0 0 0 0

0 3 26 0 0 0

0 1 9 1 0 0 0

0 2 9 0 0 0 0

0 3 15 1 0 0 0

0 3 15 0 0 0 0

0 2 12 0 0 0 0

0 3 12 1 0 0 0

0 1 11 0 0 0 0

0 0 5 2 0 0 0

0 0 14 0 0 0 0

0 2 9 0 0 0 0

0 0 5 0 0 0 0

Initial All Initial All Initial All Initial All Initial All Initial All Initial All 11 1822 1128 326 3 1 17

10 1793 1155 317 3 1 17

9 1770 1171 300 3 1 17

9 1747 1197 293 3 1 17

8 1728 1220 282 2 1 16

8 1709 1235 283 4 1 15

7 1689 1242 273 3 1 13

8 1663 1254 268 2 14

8 1643 1269 262 3 1 14

8 1615 1263 261 3 1 13

9 1588 1282 258 3 1 13

9 1588 1305 258 3 1 13

9 1558 1313 247 3 1 12

9 1518 1307 236 3 1 12

8 1513 1328 232 2 1 12

8 1483 1319 231 2 1 11

9 1462 1352 227 3 1 11

9 1453 1361 221 3 1 11

9 1437 1359 218 3 1 11

0% 55% 34% 10% 0% 0% 1%

0% 55% 35% 10% 0% 0% 1%

0% 55% 36% 9% 0% 0% 1%

0% 54% 37% 9% 0% 0% 1%

0% 53% 38% 9% 0% 0% 0%

0% 53% 38% 9% 0% 0% 0%

0% 53% 39% 8% 0% 0% 0%

0% 52% 39% 8% 0% 0%

0% 52% 40% 8% 0% 0% 0%

0% 51% 40% 8% 0% 0% 0%

0% 51% 41% 8% 0% 0% 0%

0% 50% 41% 8% 0% 0% 0%

0% 50% 42% 8% 0% 0% 0%

0% 49% 43% 8% 0% 0% 0%

0% 49% 43% 8% 0% 0% 0%

0% 49% 43% 8% 0% 0% 0%

0% 48% 44% 7% 0% 0% 0%

0% 48% 45% 7% 0% 0% 0%

0% 47% 45% 7% 0% 0% 0%

0% 45% 45% 9% 0% 0% 0%

0% 46% 46% 8% 0% 0% 0%

0% 25% 69% 6% 0% 0% 0%

0% 7% 93% 0% 0% 0% 0%

0% 17% 83% 0% 0% 0% 0%

0% 20% 80% 0% 0% 0% 0%

0% 21% 79% 0% 0% 0% 0%

0% 10% 90% 0% 0% 0%

0% 9% 82% 9% 0% 0% 0%

0% 18% 82% 0% 0% 0% 0%

0% 16% 79% 5% 0% 0% 0%

0% 17% 83% 0% 0% 0% 0%

0% 14% 86% 0% 0% 0% 0%

0% 19% 75% 6% 0% 0% 0%

0% 8% 92% 0% 0% 0% 0%

0% 0% 71% 29% 0% 0% 0%

0% 0% 100% 0% 0% 0% 0%

0% 18% 82% 0% 0% 0% 0%

0% 0% 100% 0% 0% 0% 0%

2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

Definitions:Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASSAll is defined as number of patients on ARV treatment which contains INGREDIENT;% is calculated as ratio of "All" and number of patients whose treatment is of given CLASSRitonavir - greater than 400 mg total daily dose

JAN-2016

FEB-2016

MAR-2016

APR-2016

MAY-2016

JUN-2016

JUL-2016

AUG-2016

SEP-2016

OCT-2016

NOV-2016

DEC-2016

JAN-2017

FEB-2017

MAR-2017

APR-2017

MAY-2017

JUN-2017

JUL-2017

tipranavir

0 0% 0 0%

0 0% 0 0%

0 0% 0 0%

0 0% 0 0%

0 0% 0 0%

0 0% 0 0%

0 0% 0 0%

0 0% 0 0%

0 0% 0 0%

0 0% 0 0%

0 0% 0 0%

0 0% 0 0%

0 0% 0 0%

0 0% 0 0%

0 0% 0 0%

0 0% 0 0%

0 0% 0 0%

0 0% 0 0%

0 0% 0 0%

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Initial All 1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

0%

0%

0%

0%

0%

0%

0%

0%

0%

0%

0%

0%

0%

0%

0%

0%

0%

0%

0%

0%

0%

0%

0%

0%

0%

0%

0%

0%

0%

0%

0%

0%

0%

0%

0%

0%

2.8 Number of Participants on Non-Nucleosides by INGREDIENT


JAN-2016

FEB-2016

MAR-2016

APR-2016

MAY-2016

JUN-2016

JUL-2016

AUG-2016

SEP-2016

OCT-2016

NOV-2016

DEC-2016

JAN-2017

FEB-2017

MAR-2017

APR-2017

MAY-2017

JUN-2017

JUL-2017

efavirenz etravirine nevirapine rilpivirine

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

2 0 0 0

3 0 1 1

2 0 1 1

3 1 3 2

5 0 0 3

4 0 0 2

1 1 2 0

5 0 0 2

2 0 0 2

1 2 1 1

7 1 0 0

7 0 0 3

4 0 1 0

4 0 0 1

1 0 0 1

4 0 1 4

3 0 0 1

3 0 0 0

2 0 0 0

Initial All Initial All Initial All Initial All 1032 302 855 256

1008 306 857 259

996 307 854 257

990 308 845 260

986 303 834 260

979 298 839 260

969 299 836 257

960 295 830 262

949 295 819 265

944 300 814 269

936 294 812 269

927 290 805 273

928 292 799 269

907 280 791 266

898 279 790 265

889 273 787 271

878 274 783 279

853 270 782 288

835 265 779 283

42% 12% 35% 10%

41% 13% 35% 11%

41% 13% 35% 11%

41% 13% 35% 11%

41% 13% 35% 11%

41% 13% 35% 11%

41% 13% 35% 11%

41% 13% 35% 11%

41% 13% 35% 11%

41% 13% 35% 12%

41% 13% 35% 12%

40% 13% 35% 12%

41% 13% 35% 12%

40% 12% 35% 12%

40% 13% 35% 12%

40% 12% 35% 12%

40% 12% 35% 13%

39% 12% 36% 13%

39% 12% 36% 13%

100% 0% 0% 0%

60% 0% 20% 20%

50% 0% 25% 25%

33% 11% 33% 22%

63% 0% 0% 38%

67% 0% 0% 33%

25% 25% 50% 0%

71% 0% 0% 29%

50% 0% 0% 50%

20% 40% 20% 20%

88% 13% 0% 0%

70% 0% 0% 30%

80% 0% 20% 0%

80% 0% 0% 20%

50% 0% 0% 50%

44% 0% 11% 44%

75% 0% 0% 25%

100% 0% 0% 0%

100% 0% 0% 0%

2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT


JAN-2016

FEB-2016

MAR-2016

APR-2016

MAY-2016

JUN-2016

JUL-2016

AUG-2016

SEP-2016

OCT-2016

NOV-2016

DEC-2016

JAN-2017

FEB-2017

MAR-2017

APR-2017

MAY-2017

JUN-2017

JUL-2017

dolutegravir elvitegravir maraviroc raltegravir enfuvirtide

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%

6 4 0 1 0

7 4 0 0 0

15 2 0 2 0

12 4 0 2 0

13 4 0 0 0

16 9 0 1 0

14 5 0 1 0

20 14 0 0 0

19 10 0 1 0

15 1 0 0 0

18 5 0 2 0

9 2 0 1 0

13 3 0 0 0

14 4 0 0 0

13 2 0 0 0

14 4 0 0 0

19 3 0 0 0

12 3 0 1 0

9 2 0 0 0

Initial All Initial All Initial All Initial All Initial All 1020 458 66 821 1

1062 468 60 813 1

1115 482 60 806 1

1153 491 60 799 1

1182 493 60 798 1

1216 506 58 788 1

1251 517 57 784 1

1305 533 55 774 1

1364 545 53 781 1

1412 561 53 777 1

1452 580 53 756 1

1479 587 53 762 1

1518 587 52 756 1

1560 588 48 732 1

1619 602 49 732 1

1656 596 50 722 1

1727 603 47 715 1

1759 597 49 713 1

1791 592 48 705 1

44% 20% 3% 35% 0%

45% 20% 3% 34% 0%

46% 20% 2% 33% 0%

47% 20% 2% 32% 0%

47% 20% 2% 32% 0%

48% 20% 2% 31% 0%

49% 20% 2% 30% 0%

49% 20% 2% 29% 0%

50% 20% 2% 29% 0%

51% 20% 2% 28% 0%

52% 21% 2% 27% 0%

52% 21% 2% 27% 0%

53% 20% 2% 26% 0%

54% 20% 2% 25% 0%

55% 20% 2% 25% 0%

55% 20% 2% 24% 0%

57% 20% 2% 23% 0%

57% 19% 2% 23% 0%

58% 19% 2% 23% 0%

55% 36% 0% 9% 0%

64% 36% 0% 0% 0%

79% 11% 0% 11% 0%

67% 22% 0% 11% 0%

76% 24% 0% 0% 0%

62% 35% 0% 4% 0%

70% 25% 0% 5% 0%

59% 41% 0% 0% 0%

63% 33% 0% 3% 0%

94% 6% 0% 0% 0%

72% 20% 0% 8% 0%

75% 17% 0% 8% 0%

81% 19% 0% 0% 0%

78% 22% 0% 0% 0%

87% 13% 0% 0% 0%

78% 22% 0% 0% 0%

86% 14% 0% 0% 0%

75% 19% 0% 6% 0%

82% 18% 0% 0% 0%

2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

Definitions:n is number of participants on the specified regimen class in the specified month% is ratio of n and total number of participants on ART in the specified month


MON-YYYY

Boosted PI+ 2 NRTIsn %

2285227922662244225622552225221021912169217421812155212521332108210921162099

1609166817061757178118111847191319772033207421022135216522222260230923522386

NNRTI+ 2 NRTIsn %

Integrase+ 2 NRTIsn %

Un-boosted PI+ 2 NRTIsn %

Othern %

1944192519031894188718771865183918311829181718081793177217551745173817191691

158153154154157152150142144146143143139133134133132132130

913905905908908911908909908904902900897884883875881872869

MDRTn %

61596157545657565757595863555959595861

32.78 32.61 32.39 31.99 32.03 31.93 31.55 31.26 30.82 30.39 30.33 30.33 30.01 29.79 29.68 29.36 29.18 29.19 29.01

27.89 27.54 27.21 27.00 26.79 26.58 26.45 26.01 25.76 25.62 25.35 25.14 24.97 24.84 24.42 24.30 24.05 23.71 23.37

23.08 23.87 24.39 25.05 25.29 25.64 26.19 27.06 27.81 28.48 28.93 29.23 29.73 30.35 30.92 31.48 31.95 32.45 32.97

2.27 2.19 2.20 2.20 2.23 2.15 2.13 2.01 2.03 2.05 1.99 1.99 1.94 1.86 1.86 1.85 1.83 1.82 1.80

0.88 0.84 0.87 0.81 0.77 0.79 0.81 0.79 0.80 0.80 0.82 0.81 0.88 0.77 0.82 0.82 0.82 0.80 0.84

13.10 12.95 12.94 12.95 12.89 12.90 12.88 12.86 12.77 12.66 12.58 12.51 12.49 12.39 12.29 12.19 12.19 12.03 12.01

2.11 Baseline CD4 for Antiretroviral First Starts


MON-YYYY

Definitions:First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)Baseline CD4 is defined as most recent CD4 test before ARV start

MedianCD4

16182420233425402722272522241920222412

380331365580510380320410253370390410390425220350405230340

# of Pts withCD4 < 100

# of Pts withCD4: 100-199


# of Pts withCD4 > 500

2442252282343551262

3031156722412332022

0642366666553156352

53824

103

1246736325931


# ofFirst Starts

3559

1387

13458

116

1025875

2.12 DTP Participants with PVL Measurement within previous five years, and never on ART


MON-YYYY# of Participants

with PVL test

Definitions:Patients with PVL test are defined as having at leat one PVL test within previous five years, and not reported deceased/movedNever on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month

# of Partcipantswith PVL test, and never on ART

11049111421120211249113091136511408114531148011511115531158311604116311168311709117511178111821

3054313531833217326632973332333833423366338733983419342834783493351935353567

3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants N = 7236

NorthwestNortheast

Northern Interior

East Kootenay

Thompson Cariboo Shuswap

KootenayBoundary

Okanagan

Fraser North

FraserSouth

Fraser East

Fraser East

South Vancouver Island

Central Vancouver Island

North Vancouver Island

North Shore/Coast Garibaldi


Vancouver

Richmond

July 2017

0

1 - 99

100 - 499

500 - 999

1000+

Northern

Interior

Fraser

VancouverCoastal

VancouverCoastalVancouver

Island

BY HEALTH AUTHORITY

BY HEALTH SERVICES DELIVERY AREA

EastKootenay

1

2

18

4

3

5

6

7

10

13 12

9

11

KootenayBoundary

27

26

2930

31

25

24

19

20

78

22

17

1614

23

ThompsonCaribooShuswap

1577

21

Okanagan

V4T

V1Z

V1W

V1Y

V1V

V1XV1P

0

1 - 9

10 - 49

50 - 99

1000+

N = 474

100 - 999

July 2017

3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA

0

1 - 9

10 - 19

20 - 49

50 - 99

100+

N = 122

KELOWNA BY POSTAL CODE

FraserNorth

FraserEast

FraserSouth

32

33

42

76

75

34

43

37

35

201

202

V4AV4B

V4P

V4N

V3S

V3RV3TV3V

V3W

V3XSurrey

201

South Surrey/White Rock

202

0

1 - 9

10 - 49

50 - 99

1000+

N = 1777

100 - 999

0

1 - 9

10 - 19

20 - 49

50 - 99

100+

N = 575

July 2017


FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA

SURREY BY POSTAL CODE

83

83

83

83

47

49

48

46

4445

47

38

Vancouver

Richmond



V6T V6R

V6S

V6K

V6L

V6N

V5K

V5M

V5R

V5SV6P

V5X

V5P

V5L

V6M

V6JV6H V5Z

V5Y

V5W

V5VV5N

V5T

V6A

V6G

V6EV6B

V7XV7Y

V6C

0

1 - 9

10 - 49

50 - 99

1000+

N = 3864

100 - 999

July 2017


VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA

0

1 - 9

10 - 19

20 - 49

50 - 99

100+

N = 3368

VANCOUVER BY POSTAL CODE

Westside 164

North East 163

City Centre 161

Midtown 165

South 166

Downtown Eastside 162

8572

72

85

7184

70 69

66

6261

6867

6564

63

North Vancouver Island

Central Vancouver Island

South Vancouver Island

V9C

V9B

V9E

V8Z

V8Y

V8X V8N

V8P

V8R

V8S

V9A V8T

V8V

V8W

0

1 - 9

10 - 49

50 - 99

1000+

N = 880

100 - 999

July 2017


VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA

0

1 - 9

10 - 19

20 - 49

50 - 99

100+

N = 429

VICTORIA BY POSTAL CODE

July 2017

81

94

87

60

59

57

28

55

56

51

92

50

53

5488

80

52

Northwest

Northeast

NorthernInterior

V2N

V2K

V2M

V2L

0

0

1 - 9

1 - 9

10 - 49

10 - 19

50 - 99

20 - 49

50 - 99

1000+

100+


NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA

PRINCE GEORGE BY POSTAL CODE

N =

N =

206

94

100 - 999

4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

Definitions:Currently treated with ARVs defined as being on ARV therapy in the specified monthMed CD4 and PVL tests defined as most recent tests (as of specified month)

EASTKOOTENAY

KOOTENAYBOUNDARY

OKANAGAN

THOMPSON/CARIBOO/SHUSWAP

20-3435-4950+

0-1920-3435-4950+

0-1920-3435-4950+

0-1920-3435-4950+

***

****

****

****

***

****

****

0183782

HSDA Age Group Ever

treated with ARVsCurrently

treated with ARVs

Total HSDA:

Total HSDA:

Total HSDA:

Total HSDA:Total HA: 628 834 474

35

71

347

175

48

93

460

233

24

50

263

137

Alive***

****

****

****

Age Group Ever


treated with ARVsAlive0-1920-3435-4950+

565

196568

****

564

172387

Total HA: 628 834 474

GenderEver


treated with ARVsAliveMaleFemale

662172

37599

491137

Currently treated with ARVs # of patients 580 3553

Med Age Med CD4 Med PVLTotal HA: 474

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

Definitions:Currently treated with ARVs defined as being on ARV therapy in the specified monthTreatment Duration defined as number of years since ARV initiation

EASTKOOTENAY

KOOTENAYBOUNDARY

OKANAGAN

THOMPSON/CARIBOO/SHUSWAP

10 years or more5 years or more<5 years




***

25169

1356266

643340

HSDATreatmentDuration

Currentlytreated with ARVs

Total HSDA:

Total HSDA:

Total HSDA:

Total HSDA:Total HA: 628 474

35

71

347

175

24

50

263

137

Alive195

11

381914

1908077

923647

Currentlytreated with ARVsAlive


236115123

339140149

Total HA: 628 474

TreatmentDuration


4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

Definitions:Currently prescribing/treated defined as prescribing/being treated in the previous 6 months# of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s)reside in another HA

****

Total: 91

# of Patientsseeking Physician's care

out of HA EAST KOOTENAYKOOTENAY BOUNDARYOKANAGANTHOMPSON/CARIBOO/SHUSWAP

HSDA of Patient Residency

3764

200127

Total: 428

# of Physicansever

prescribed ARVs HSDA of Physician Residency

# of Physicanscurrently

prescribing ARVs

# of Patientsever

treated by Physicians

# of Patientscurrently


53112715452

14246334

2336

269120

1332 135 448

EAST KOOTENAYKOOTENAY BOUNDARYOKANAGANTHOMPSON/CARIBOO/SHUSWAP


4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority


FRASER EAST

FRASER NORTH

FRASER SOUTH

0-1920-3435-4950+

0-1920-3435-4950+

0-1920-3435-4950+

625

120263

13116385796

997

424679

51481

153

****

670

305380

HSDA Age Group Ever


treated with ARVs

Total HSDA:

Total HSDA:


335

981

936

414

1310

1209

253

763

761

Alive6

24109196

13115345508

995

371461

Age Group Ever



28238929

1738

14171654938

28234825

1165Total HA: 2252 2933 1777

GenderEver



2264669

1377400

1716536




4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration FRASER Health Authority


FRASER EAST

FRASER NORTH

FRASER SOUTH




1208449

350195218

350207204



Total HSDA:

Total HSDA:


335

981

936

253

763

761

Alive1719965

488244249

446249241



820486471

1105592555

Total HA: 2252 1777

TreatmentDuration


4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority


177648517

Total: 1342


out of HA FRASER EASTFRASER NORTHFRASER SOUTH


131238204

Total: 573

# of Physicansever



prescribing ARVs

# of Patientsever




44014841226

425746

97261347

3150 145 705

FRASER EASTFRASER NORTHFRASER SOUTH


4.7 Distribution of Participants in BC-CfE Registries by Age and Gender VANCOUVER COASTAL Health Authority


NORTH SHORE/COAST GARIBALDI

RICHMOND

VANCOUVER

0-1920-3435-4950+

0-1920-3435-4950+

0-1920-3435-4950+

****

****

50460

17004335

02271

188

****

5355

10971998

HSDA Age Group Ever


treated with ARVs

Total HSDA:

Total HSDA:


326

160

4565

467

206

6545

281

128

3455

Alive****

****

47449

14882581

Age Group Ever



54510

18484806

6396

12032259

51498

16192883

Total HA: 5051 7218 3864

GenderEver


treated with ARVsAlive

MaleFemale

26344872

03413451

24445604




4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER COASTAL Health Authority


NORTH SHORE/COAST GARIBALDI

RICHMOND

VANCOUVER



10 years or more5 years or more<5 yearsNever on ART

1386776

553439

1741926788

0



Total HSDA:

Total HSDA:


326

160

4565

281

128

3455

Alive1697483

783943

24201213932

0


10 years or more5 years or more<5 yearsNever on ART

19341027903

0

266713261058

0Total HA: 5051 3864

TreatmentDuration


4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries VANCOUVER COASTAL Health Authority


***

Total: 106


out of HA NORTH SHORE/COAST GARIBALDIRICHMONDVANCOUVER


15242

558Total: 752

# of Physicansever



prescribing ARVs

# of Patientsever



treated by Physicians 390272

10261

5614

214

10396

532510923 284 5524

NORTH SHORE/COAST GARIBALDIRICHMONDVANCOUVER


4.10 Distribution of Participants in BC-CfE Registries by Age and Gender VANCOUVER ISLAND Health Authority


CENTRALVANCOUVERISLAND

NORTHVANCOUVERISLAND

SOUTHVANCOUVERISLAND

0-1920-3435-4950+

0-1920-3435-4950+

0-1920-3435-4950+

****

****

561

235663

****

****

****

HSDA Age Group Ever


treated with ARVs

Total HSDA:

Total HSDA:


296

117

691

415

154

964

246

96

538

Alive****

****

558

199429

Age Group Ever



10101369

1053

570

263542

1095

320679

Total HA: 1104 1533 880

GenderEver



1249284

717163

899205




4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority


CENTRALVANCOUVERISLAND

NORTHVANCOUVERISLAND

SOUTHVANCOUVERISLAND




1185969

492324

260132146



Total HSDA:

Total HSDA:


296

117

691

246

96

538

Alive1417382

582930

364163164



427214239

563265276

Total HA: 1104 880

TreatmentDuration


4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries VANCOUVER ISLAND Health Authority


4234

101Total: 177


out of HA CENTRAL VANCOUVER ISLANDNORTH VANCOUVER ISLANDSOUTH VANCOUVER ISLAND


178125193

Total: 496

# of Physicansever



prescribing ARVs

# of Patientsever




798251

1625

784340

21178

5492674 161 838

CENTRAL VANCOUVER ISLANDNORTH VANCOUVER ISLANDSOUTH VANCOUVER ISLAND


4.13 Distribution of Participants in BC-CfE Registries by Age and Gender NORTHERN Health Authority


NORTH EAST

NORTH WEST

NORTHERN INTERIOR

0-1920-3435-4950+

0-1920-3435-4950+

0-1920-3435-4950+

****

****

72589

134

****

06

1925

****

HSDA Age Group Ever


treated with ARVs

Total HSDA:

Total HSDA:


39

68

185

47

103

255

22

50

134

Alive****

****

7227383

Age Group Ever



940

143213

****

933

112138

Total HA: 292 405 206

GenderEver



252153

12878

179113




4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration NORTHERN Health Authority


NORTH EAST

NORTH WEST

NORTHERN INTERIOR




796

122711

385046



Total HSDA:

Total HSDA:


39

68

185

22

50

134

Alive16158

223115

636062



578663

10110685

Total HA: 292 206

TreatmentDuration


4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries NORTHERN Health Authority


71221

Total: 40


out of HA NORTH EASTNORTH WESTNORTHERN INTERIOR


3366

102Total: 201

# of Physicansever



prescribing ARVs

# of Patientsever




59149414

71916

1028

180622 42 218

NORTH EASTNORTH WESTNORTHERN INTERIOR


4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender


INTERIOR

FRASER

VANCOUVERCOASTAL

VANCOUVERISLAND

NORTHERN

EAST KOOTENAYKOOTENAY BOUNDARYOKANAGANTHOMPSON/CARIBOO/SHUSWAP

FRASER EASTFRASER NORTHFRASER SOUTH

NORTH SHORE/COAST GARIBALDIRICHMONDVANCOUVER

CENTRAL VANCOUVER ISLANDNORTH VANCOUVER ISLANDSOUTH VANCOUVER ISLAND

NORTH EASTNORTH WESTNORTHERN INTERIOR

107

3340

4185

106

4714

813

752374

105899

****

254261

228

420

431230

52755

HA HSDAEver


treated with ARVs

Total HA:

Total HA:

Total HA:

Total HA:

Total HA: Total: 952 1535 790

51

162

536

97

106

90

232

874

172

167

40

128

450

85

87

Alive****

325377

269

501

491434

83266

GenderEver



980555

485305

591361


Med Age Med CD4 Med PVLTotal: 790


5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicstat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

Delavirdine (Rescriptor, DLV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from ViiV Healthcare.

Descovy (DSC): the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay, DTG): an INTEGRASE INHIBITOR from ViiV Healthcare.

Efavirenz (Sustiva, Auro efavirenz, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine (FTC): a NUCLEOSIDE ANALOG from Gilead Sciences. It its currently available as a component of TRUVADA and other combinations. Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intelence, ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya (GNV): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Indinavir (Crixivan, IDV): a PROTEASE INHIBITOR from Merck.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare’s trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

Maraviroc (Celsentri, MVC): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV’s reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.

Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant, RPV): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

Date post:	10-Sep-2020
Category:	Documents
Upload:	others
View:	1 times
Download:	0 times

B.C. HIV/AIDS Drug Treatment Programcfenet.ubc.ca/sites/default/files/uploads/publications/...2....

Documents